Quick-Med Technologies, a life sciences company that is developing innovative technologies for the healthcare and consumer markets, announced that it has licensed its Stay Fresh technology to Sarasota Medical Products for use in Hydrocolloids in SMP's Ostomy and Advanced Wound Care product lines.

"We are very excited to enter this new product segment of hydrocolloids with a partner that is close to home, manufacturing high quality wound care products for global distribution. Our antimicrobial technology will greatly expand the number of patients we can provide with safe, effective antimicrobial products in support of infection prevention and control programs. Our technologies are specifically designed to be effective against resistant organisms like MRSA, and to prevent new resistant bacteria from emerging" said Bernd Liesenfeld, Quick-Med’s President.

This is the initial commercial application of Quick-Med’s newest Stay Fresh format: an antimicrobial superabsorbent powder (SAP) that can be directly substituted for a conventional SAP to provide strong and durable antimicrobial activity in applications including health care and hygiene.

"Hydrocolloids are excellent at maintaining the correct moisture balance to optimize wound closure and healing," notes Professor Gregory Schultz, Director of the Institute for Wound Research and Professor of Obstetrics and Gynecology at the University of Florida. "Stay Fresh antimicrobial activity is based on peroxide, which is the chemical mechanism utilized by the body’s own neutrophils to kill invading pathogens, and therefore provides optimum biological safety."

"Sarasota Medical Products manufactures a broad array of premium quality ostomy and advanced wound care products that will now include Quick-Med’s Stay Fresh antimicrobial technology," said Dr. Walt F Leise III, SMP’s CEO and President. Sarasota Medical provides product to these markets under a broad range of private labels.

The US market for advanced wound care is growing from $3.4 billion in 2010 to an expected $4.6 billion by 2016, and Hydrocolloids represented approximately $800m of the AWC market in 2011.